Cargando…
Metastatic Castration-Resistant Prostate Cancer: Two Case Reports of Dramatic Response with Abiraterone Acetate in Patients Heavily Pretreated with Chemotherapy
Metastatic castration-resistant prostate cancer (mCRPC) with visceral involvement requires new, effective and safe treatments after chemotherapy failure. The CYP17A1 inhibitor abiraterone acetate has been approved as a treatment for mCRPC, both after docetaxel chemotherapy and more recently for pati...
Autores principales: | Dupuy, Laura, Long, Jérôme, Ranchoup, Yves |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3725023/ https://www.ncbi.nlm.nih.gov/pubmed/23898269 http://dx.doi.org/10.1159/000353131 |
Ejemplares similares
-
Chromonychia Secondary to Chemotherapy
por: Lopes, Marien, et al.
Publicado: (2013) -
EML4-ALK-Positive Pulmonary Adenocarcinoma with an Unusual Metastatic Pattern: A Case Report
por: Diem, Stefan, et al.
Publicado: (2013) -
Lateral and Dorsal Column Hyperintensity on Magnetic Resonance Imaging in a Patient with Myelopathy Associated with Intrathecal Chemotherapy
por: Saito, Fumine, et al.
Publicado: (2013) -
Sequencing of Cabazitaxel in Metastatic Castrate-Resistant Prostate Cancer: A Case Report
por: Colbourn, Donald
Publicado: (2012) -
Dramatic and Delayed Response to Doxorubicin-Dacarbazine Chemotherapy of a Giant Desmoid Tumor: Case Report and Literature Review
por: Monneur, Audrey, et al.
Publicado: (2013)